头孢哌酮/舒巴坦联合莫西沙星治疗慢性阻塞性肺疾病合并急性下呼吸道感染的临床疗效

Clinical efficacy of cefoperazone/sulbactam combined with moxifloxacin in the treatment of chronic obstructive pulmonary disease complicated with acute lower respiratory tract infection

目的探讨头孢哌酮/舒巴坦联合莫西沙星治疗慢性阻塞性肺疾病合并急性下呼吸道感染的临床疗效。方法选取汕头市龙湖区第二人民医院2018—2020年收治的慢性阻塞性肺疾病合并急性下呼吸道感染患者120例,依据治疗方法不同分为对照组与试验组,各60例。对照组予以头孢哌酮/舒巴坦注射液治疗,试验组在对照组基础上予以莫西沙星治疗。比较2组治疗前后白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)、白介素6(IL-6)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/用力肺活量(FVC),细菌清除率,并观察2组不良反应发生情况。结果治疗后,试验组WBC、CRP、PCT及IL-6低于对照组,FEV_(1)、FEV_(1)/FVC高于对照组(P<0.05)。试验组细菌清除率高于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论头孢哌酮/舒巴坦联合莫西沙星治疗慢性阻塞性肺疾病合并急性下呼吸道感染的临床疗效确切,可有效减轻炎性反应,改善肺功能,且安全性较高。

Objective To observe the clinical efficacy of cefoperazone/sulbactam combined with moxifloxacin in the treatment of chronic obstructive pulmonary disease complicated with acute lower respiratory tract infection.Methods A total of 120 cases of patients with chronic obstructive pulmonary disease complicated with acute lower respiratory tract infection were selected from 2018 to 2020 in the Second People's Hospital of Longhu District,Shantou City,which were divided into control group and experimental group according to different treatment methods,60 cases in each group.The control group was treated with cefoperazone/sulbactam injection,the experimental group was treated with moxifloxacin on the basis of the control group.White blood cell count(WBC),C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6),forced expiratory volume in the first second(FEV_(1)),FEV_(1)/forced vital capacity(FVC)before and after treatment,bacterial clearance rate were compared between the two groups,and the incidence of adverse reactions were observed.Results After treatment,WBC,CRP,PCT and IL-6 of the experimental group were lower than those of the control group,while FEV_(1) and FEV_(1)/FVC were higher than those of the control group(P<0.05).The bacterial clearance rate of the experimental group was higher than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Cefoperazone/sulbactam combined with moxifloxacin have an exact clinical effect for chronic obstructive pulmonary disease complicated with acute lower respiratory tract infection,which can effectively reduce inflammatory reaction and improve pulmonary function,and with high safety.